Absence of Rejection in a Facial Allograft Recipient with a Positive Flow Crossmatch 24 Months after Induction with Rabbit Anti-Thymocyte Globulin and Anti-CD20 Monoclonal Antibody
Background. Donor-specific antibodies (DSA) to human leukocyte antigen increase the risk of accelerated rejection and allograft damage and reduce the likelihood of successful transplantation. Patients with full-thickness facial burns may benefit from facial allotransplantation. However, they are at...
Main Authors: | Bruce E. Gelb, J. Rodrigo Diaz-Siso, Natalie M. Plana, Adam Jacoby, William J. Rifkin, Kimberly S. Khouri, Daniel J. Ceradini, Eduardo D. Rodriguez |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2018-01-01
|
Series: | Case Reports in Transplantation |
Online Access: | http://dx.doi.org/10.1155/2018/7691072 |
Similar Items
-
Comparison of Alemtuzumab and Anti-thymocyte Globulin Treatment for Acute Kidney Allograft Rejection
by: Marieke van der Zwan, et al.
Published: (2020-07-01) -
Usefulness of valacyclovir prophylaxis for cytomegalovirus infection after anti-thymocyte globulin as rejection therapy
by: Eun Jeong Ko, et al.
Published: (2019-03-01) -
Anti-thymocyte globulin in haematology: Recent developments
by: Salahuddin Siddiqui, et al.
Published: (2019-01-01) -
Anti-thymocyte globulin versus basiliximab induction in renal transplant recipients: Long-term outcome
by: Sailaja Kesiraju, et al.
Published: (2014-01-01) -
Relationship Between Post-transplant Lymphoproliferative Disorder and Anti-Thymocyte Globulin or Anti-Lymphocyte Globulin
by: Kh. Rahbar, et al.
Published: (2007-02-01)